Company / Cash & Equivalents
Becton Dickinson Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$641.0M
FY2025
5-year range
$641.0M / $2.3B
FY2021-FY2025
Trend
-62.7%
vs FY2024
Sector context
#39 of 148
Health Care
What the data says
At $641M, Becton Dickinson's cash & equivalents ranks #39 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $536M in FY2019 to $14.2B in FY2017.
Based on SEC 10-K filings.
$641M in FY2025 with a 5-year CAGR of -25.7%.
Declined from $1.4B to $641M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -13.9%
- 5-Year CAGR
- -25.7%
- 10-Year CAGR
- -
Sector benchmark
#39 of 148 in Health CareTop 26% of 148This company $641.0M Sector average $1.2B
▼
-45.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -25.7%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 62.7% year-over-year.
- Ranks #39 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score 1.16 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $641.0M | -62.7% |
| FY2024 | $1.7B | +21.3% |
| FY2023 | $1.4B | +40.8% |
| FY2022 | $1.0B | -55.9% |
| FY2021 | $2.3B | -19.2% |
| FY2020 | $2.8B | +427.1% |
| FY2019 | $536.0M | -53.0% |
| FY2018 | $1.1B | -92.0% |
| FY2017 | $14.2B | +820.1% |
| FY2016 | $1.5B | +8.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026